Systemic Lupus Erythematosus

  • Joo Young Shin
Part of the Retina Atlas book series (RA)


Systemic lupus erythematosus (SLE), a systemic, connective tissue disease that can affect multiple organ systems, affects women, especially Asian and African women more commonly (Silpa-archa et al. 2016). Up to one-third of SLE patients experience some kind of ocular manifestation (Palejwala et al. 2012), keratoconjunctivitis sicca being the most common form, and retinal and choroidal involvement being most associated with visual impairment (Sivaraj et al. 2007; Palejwala et al. 2012). Although, the prevalence of SLE as a cause of uveitis was estimated to be 0.47% in a recent review of the literature (Gallagher et al. 2015), ocular involvement in SLE is important as it may correlate with systemic disease activity and precede other systemic symptoms.


  1. Ahn HM, Choi KS. Choroidoretinopathy and secondary angle closure attack in systemic lupus erythematosus: a case report. J Korean Ophthalmol Soc. 2016;57(11):1801–5. Scholar
  2. Aronson AJ, Ordonez NG, Diddie KR, Ernest JT. Immune-complex deposition in the eye in systemic lupus erythematosus. Arch Intern Med. 1979;139(11):1312–3.CrossRefGoogle Scholar
  3. Au A, O’Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clin Exp Ophthalmol. 2004;32(1):87–100.CrossRefGoogle Scholar
  4. Davies JB, Rao PK. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2008;19(6):512–8.CrossRefGoogle Scholar
  5. Dooley MA, Houssiau F, Aranow C, D’Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63–72. Scholar
  6. Gallagher K, Viswanathan A, Okhravi N. Association of systemic lupus erythematosus with uveitis. JAMA Ophthalmol. 2015;133(10):1190–3. Scholar
  7. Halmay O, Ludwig K. Bilateral band-shaped deep keratitis and iridocyclitis in systemic lupus erythematosus. Br J Ophthalmol. 1964;48(10):558–62.CrossRefGoogle Scholar
  8. Heron E, Gutzwiller-Fontaine M, Bourcier T. Scleritis and episcleritis: diagnosis and treatment. Rev Med Interne. 2014;35(9):577–85. Scholar
  9. Jabs DA, Fine SL, Hochberg MC, Newman SA, Heiner GG, Stevens MB. Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol. 1986;104(4):558–63.CrossRefGoogle Scholar
  10. Kim SB, Cho WH, Chang MH. A case of severe vaso-occlusive retinopathy as the first manifestation associated with systemic lupus erythematosus. J Korean Ophthalmol Soc. 2013;54(3):518–23. Scholar
  11. Kurup S, Lew J, Byrnes G, Yeh S, Nussenblatt R, Levy-Clarke G. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol. 2009;87(3):349–52. Scholar
  12. Lee WJ, Cho HY, Lee YJ, Lee BR, Shin JP. Intravitreal bevacizumab for severe vaso-occlusive retinopathy in systemic lupus erythematosus. Rheumatol Int. 2013;33(1):247–51. Scholar
  13. Levine RA, Ward PA. Experimental acute immunologic ocular vasculitis. Am J Ophthalmol. 1970;69(6):1023–31.CrossRefGoogle Scholar
  14. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. Scholar
  15. Nguyen QD, Uy HS, Akpek EK, Harper SL, Zacks DN, Foster CS. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9(4):288–98. Scholar
  16. Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898. Scholar
  17. Read RW, Chong LP, Rao NA. Occlusive retinal vasculitis associated with systemic lupus erythematosus. Arch Ophthalmol. 2000;118(4):588–9.CrossRefGoogle Scholar
  18. Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016;100(1):135–41. Scholar
  19. Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007;46(12):1757–62. Scholar
  20. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum. 1988;31(9):1105–10.CrossRefGoogle Scholar
  21. Stavrou P, Murray PI, Batta K, Gordon C. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. Br J Ophthalmol. 2002;86(4):474–5.CrossRefGoogle Scholar
  22. Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its management. J Ophthalmol. 2014;2014:197675. Scholar
  23. Touma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. Expert Opin Biol Ther. 2013;13(5):723–37. Scholar
  24. Yen YC, Weng SF, Chen HA, Lin YS. Risk of retinal vein occlusion in patients with systemic lupus erythematosus: a population-based cohort study. Br J Ophthalmol. 2013;97(9):1192–6. Scholar
  25. Zink JM, Singh-Parikshak R, Johnson CS, Zacks DN. Hypopyon uveitis associated with systemic lupus erythematosus and antiphospholipid antibody syndrome. Graefes Arch Clin Exp Ophthalmol. 2005;243(4):386–8. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Joo Young Shin
    • 1
  1. 1.Department of OphthalmologyCollege of Medicine, Seoul National University, SMG-SNU Boramae Medical CenterSeoulSouth Korea

Personalised recommendations